Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Abstract on results of the monotherapy portion of Phase 2 ONA-XR clinical trial in granulosa cell tumors of the ovary accepted for oral presentation at the 2022 ASCO Annual Meeting Preclinical data presented at AACR Annual Meeting showcased potential of ONA-XR and CLDN6xCD3 bispecific development program PHILADELPHIA, May 11, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treat
Lead clinical-stage oral progesterone receptor (PR) antagonist ONA-XR demonstrates monotherapy clinical activity in advanced granulosa cell tumor of the ovary Trial advanced to second stage to evaluate combination of ONA-XR with oral antiestrogen PHILADELPHIA, May 05, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced